Illumina, Inc. (NASDAQ: ILMN) today announced it has completed the acquisition of GenoLogics Life Science Software Inc., a developer of industry leading laboratory information management systems (LIMS) for life sciences organizations.

"We look forward to working with the talented team at GenoLogics and to further integrate their life science software as part of the overall Illumina informatics solution," said Francis deSouza, President of Illumina. “Adopted by more than 120 genomic labs worldwide, GenoLogics’s Clarity LIMS software strengthens our industry leading portfolio of genetic analysis solutions.”

The completion of the acquisition demonstrates Illumina’s commitment to drive the adoption of sequencing in new markets and improve the genomic workflow. GenoLogics’ Clarity LIMS™ software enables lab efficiencies and improved sample throughput with increased accuracy, fast turnaround, sample traceability, and preconfigured instrument integrations.

Illumina, Inc.Investors:Rebecca Chambers, 858-255-5243rchambers@illumina.comorMedia:Eric Endicott, 858-882-6822pr@illumina.com

Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Illumina Charts.
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Illumina Charts.